NCT00143806

Transitioning From Cyclosporine to Alefacept in Psoriasis

Investigator-Initiated, Use Study of Alefacept (Amevive) in Combination With Tapering Doses of Cyclosporine in Patients With Moderate to Severe Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (planned)
• Sponsor: University of Medicine and Dentistry of New Jersey · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.

Detailed description

The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept. Patients in the study are well controlled on cyclosporine and desire to switch to alefacept. The study is done in three phases. In Phase 1 (12 week duration) the two drugs will be overlapped, with cyclosporine slowly tapering. Both drugs will be discontinued after 12 weeks. In Phase 2 (12 weeks duration), patients are off both drugs. In Phase 3 (24 weeks long), patients are on a second course of alefacept alone for 12 weeks and then off for 12 weeks. Topical and UV light treatments are allowed throughout the study. Total length of study is one year.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Transitioning patients from cyclosporine to alefacept

Timeline

• Start date: 2003-10-01
• Completion: 2007-05-01
• First posted: 2005-09-02
• Last updated: 2009-01-05

Locations

1 site across 1 country: United States